학술논문
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Document Type
article
Author
Pierre Fenaux; Aristoteles Giagounidis; Dominik Selleslag; Odile Beyne-Rauzy; Moshe Mittelman; Petra Muus; Stephen D. Nimer; Eva Hellström-Lindberg; Bayard L. Powell; Agnes Guerci-Bresler; Mikkael A. Sekeres; H. Joachim Deeg; Consuelo del Cañizo; Peter L. Greenberg; Jamile M. Shammo; Barry Skikne; Xujie Yu; Alan F. List
Source
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-8 (2017)
Subject
Language
English
ISSN
1756-8722
Abstract
Abstract Background Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results A total of 33.9, 34.3, and 31.8% patients were aged